[go: up one dir, main page]

ES2063036T3 - Compuestos (aralquil-sustituido) heterociclicos. - Google Patents

Compuestos (aralquil-sustituido) heterociclicos.

Info

Publication number
ES2063036T3
ES2063036T3 ES88305429T ES88305429T ES2063036T3 ES 2063036 T3 ES2063036 T3 ES 2063036T3 ES 88305429 T ES88305429 T ES 88305429T ES 88305429 T ES88305429 T ES 88305429T ES 2063036 T3 ES2063036 T3 ES 2063036T3
Authority
ES
Spain
Prior art keywords
substituted
aralquil
hetero
cyclic compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88305429T
Other languages
English (en)
Inventor
Philip Neil Edwards
Michael Stewart Large
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10618970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2063036(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ES2063036T3 publication Critical patent/ES2063036T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

UN COMPUESTO HETEROCICLICO (ARILALQUIL SUSTITUIDO) DE FORMULA (I), DONDE SE DETALLAN LOS DISTINTOS GRUPOS Y FORMULAS QUE PUEDEN SIGNIFICAR LA LETRAS DE DICHA FORMULA. SE INDICAN TAMBIEN LAS SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS COMPUESTOS.
ES88305429T 1987-06-16 1988-06-14 Compuestos (aralquil-sustituido) heterociclicos. Expired - Lifetime ES2063036T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878714013A GB8714013D0 (en) 1987-06-16 1987-06-16 (substituted-aralkyl)heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2063036T3 true ES2063036T3 (es) 1995-01-01

Family

ID=10618970

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88305429T Expired - Lifetime ES2063036T3 (es) 1987-06-16 1988-06-14 Compuestos (aralquil-sustituido) heterociclicos.

Country Status (21)

Country Link
US (2) US4935437A (es)
EP (1) EP0296749B1 (es)
JP (1) JP2609290B2 (es)
AT (1) ATE113277T1 (es)
AU (1) AU605872B2 (es)
CA (1) CA1337420C (es)
DE (1) DE3851914T2 (es)
DK (1) DK174573B1 (es)
ES (1) ES2063036T3 (es)
FI (1) FI97804C (es)
GB (1) GB8714013D0 (es)
HU (1) HU211142A9 (es)
IE (1) IE65570B1 (es)
IL (1) IL86499A (es)
LU (1) LU88778I2 (es)
MX (1) MX9202876A (es)
NL (1) NL970012I2 (es)
NO (2) NO170080C (es)
NZ (1) NZ225037A (es)
PT (1) PT87720B (es)
ZA (1) ZA883691B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
NZ236440A (en) * 1989-12-15 1993-07-27 Merck & Co Inc Reversal of sexual phenotype in poultry using an inhibitor of steroid biotransformation and/or aromatase inhibitor, poultry produced by this process
AU7124691A (en) * 1990-02-27 1991-08-29 Ciba-Geigy Ag Benzofurans
EP0457716A1 (de) * 1990-04-20 1991-11-21 Ciba-Geigy Ag Naphthalinderivate
TW224461B (es) * 1990-09-18 1994-06-01 Ciba Geigy Ag
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
KR100219760B1 (ko) * 1996-03-13 1999-09-01 김성환 보온 단열재
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
WO2005105762A1 (en) * 2004-05-05 2005-11-10 Natco Pharma Limited Improved process for the preparation of high purity anastrozole
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0414120D0 (en) * 2004-06-24 2004-07-28 Generics Uk Ltd Novel processes and intermediates
US20060035950A1 (en) * 2004-08-09 2006-02-16 Mohammed Alnabari Novel processes for preparing substantially pure anastrozole
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
US20060189670A1 (en) * 2005-02-22 2006-08-24 Glenmark Pharmaceuticals Limited Process for the preparation of anastrozole and intermediates thereof
EP1705168A1 (en) * 2005-03-21 2006-09-27 Helm AG Improved process for side-chain bromination of alkyl-benzenes
KR20080000621A (ko) * 2005-04-06 2008-01-02 시코르, 인크. 항암 약물의 제조 방법
US20070032660A1 (en) * 2005-06-27 2007-02-08 Alessandro Pontiroli Purification process for Anastrozole intermediate
JP2008511684A (ja) * 2005-06-27 2008-04-17 シコール インコーポレイティド アナストロゾール中間体についての精製方法
EP2397472A1 (en) 2005-09-30 2011-12-21 Cadila Healthcare Limited A process for the preparation of a benzylbromide intermediates
US20080207915A1 (en) * 2005-10-05 2008-08-28 Radhakrishnan Tarur Venkatasub Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile)
WO2007039919A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Crystalline forms of anastrozole
US20070100148A1 (en) * 2005-10-31 2007-05-03 Veerender Murki Process for preparing anastrozole
WO2007105231A1 (en) * 2006-03-10 2007-09-20 Shilpa Medicare Ltd. Improved process for high purity anastrozole
AR061016A1 (es) * 2006-05-19 2008-07-30 Synthon Bv Proceso para la purificacion de anastrozol
WO2007141799A1 (en) * 2006-06-05 2007-12-13 Cadila Healthcare Limited A process for preparing pure anastrozole
WO2008034644A2 (en) * 2006-09-22 2008-03-27 Synthon B.V. Process for making anastrozole
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7989636B2 (en) * 2006-10-17 2011-08-02 Cipla Limited Process for the preparation of pure anastrozole
US20080177081A1 (en) * 2007-01-19 2008-07-24 Formosa Laboratories, Inc. Process for Preparation of Anastrozole
CN101307027B (zh) * 2007-05-17 2011-09-07 杜焕达 一种阿那曲唑的新的制备方法
WO2009018811A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
SG185311A1 (en) 2007-10-16 2012-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
US20110104158A1 (en) * 2008-04-15 2011-05-05 Harbeson Scott L Deuterium bearing analogs of anastrozole as aromatase inhibitors for the treatment of breast cancer
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
DE102010046464A1 (de) 2009-03-19 2011-04-21 Amw Gmbh Transdermales System mit Aromatasehemmer
EP2343278A1 (en) 2010-01-07 2011-07-13 Hexal AG A process for preparing trisubstituted phenyl derivatives comprising a (1H-1,2,4-triazol-1-yl)alkyl group
DE102010026883A1 (de) 2010-03-11 2011-12-15 Amw Gmbh Transdermales System mit Aromatasehemmer
US20150031656A1 (en) 2012-02-29 2015-01-29 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CN103172580B (zh) * 2013-03-29 2015-04-22 凯莱英医药集团(天津)股份有限公司 一种阿那曲唑的制备方法
ITRM20130285A1 (it) 2013-05-14 2014-11-15 Corden Pharma Latina S P A Con Uni Co Socio Metodo per la preparazione di anastrozolo di grado farmaceutico
CN103342663B (zh) * 2013-07-15 2015-07-29 凯莱英医药集团(天津)股份有限公司 一种阿那曲唑关键中间体的制备方法
CN104387332B (zh) * 2014-11-27 2016-04-13 江苏正大清江制药有限公司 一种合成芳香化酶抑制剂的方法
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
CN106083748B (zh) * 2016-06-21 2019-08-16 扬子江药业集团江苏海慈生物药业有限公司 一种阿那曲唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431407C2 (de) * 1974-06-29 1982-12-02 Bayer Ag, 5090 Leverkusen 1,2,4-Triazol-1-yl-alkanone und -alkanole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Fungizide
JPS55313A (en) * 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
CA1134828A (en) * 1978-12-28 1982-11-02 Tadao Tanouchi Pyridine derivatives
NZ206968A (en) * 1983-02-02 1986-06-11 Lilly Co Eli Pyrimidine derivatives pharmaceutical formulations
US4755526A (en) * 1984-06-18 1988-07-05 Eli Lilly And Company Method of inhibiting aromatase
US4801594A (en) * 1984-06-18 1989-01-31 Eli Lilly And Company Aromatase inhibitors
US4766140A (en) * 1984-06-18 1988-08-23 Eli Lilly And Company Method of inhibiting aromatase
GB2162513B (en) * 1984-06-25 1988-01-20 Toyama Chemical Co Ltd Dihydropyridine derivatives
US4699652A (en) * 1985-07-22 1987-10-13 Hoffmann-La Roche Inc. Fungicidal pyridine derivatives for use in agriculture
EP0228995A1 (de) * 1985-12-20 1987-07-15 Ciba-Geigy Ag Mikrobizide
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3860278D1 (de) * 1987-01-21 1990-08-09 Ciba Geigy Ag Mikrobizides mittel.

Also Published As

Publication number Publication date
CA1337420C (en) 1995-10-24
NO882628L (no) 1988-12-19
NL970012I2 (nl) 1997-07-01
DE3851914D1 (de) 1994-12-01
LU88778I2 (fr) 1996-11-05
EP0296749B1 (en) 1994-10-26
JPS6419067A (en) 1989-01-23
GB8714013D0 (en) 1987-07-22
DK174573B1 (da) 2003-06-23
FI882882A0 (fi) 1988-06-16
MX9202876A (es) 1992-06-30
PT87720B (pt) 1992-10-30
USRE36617E (en) 2000-03-14
NO882628D0 (no) 1988-06-15
NO170080C (no) 1992-09-09
HK1000206A1 (en) 1998-02-06
JP2609290B2 (ja) 1997-05-14
ATE113277T1 (de) 1994-11-15
HU211142A9 (en) 1995-10-30
IE881505L (en) 1988-12-16
IL86499A (en) 1997-09-30
NO170080B (no) 1992-06-01
NO1997006I1 (no) 1997-05-16
FI97804B (fi) 1996-11-15
EP0296749A1 (en) 1988-12-28
NZ225037A (en) 1991-10-25
NL970012I1 (nl) 1997-05-01
FI97804C (fi) 1997-02-25
FI882882A7 (fi) 1988-12-17
AU1691188A (en) 1988-12-22
US4935437A (en) 1990-06-19
DE3851914T2 (de) 1995-03-23
AU605872B2 (en) 1991-01-24
IE65570B1 (en) 1995-11-01
DK330488D0 (da) 1988-06-16
ZA883691B (en) 1989-02-22
PT87720A (pt) 1988-07-01
DK330488A (da) 1988-12-17
IL86499A0 (en) 1988-11-15

Similar Documents

Publication Publication Date Title
ES2063036T3 (es) Compuestos (aralquil-sustituido) heterociclicos.
UY24555A1 (es) Nuevos compuestos
ES2017611T3 (es) Tiazoles sustituidos y su uso como fungicidas.
MX9306986A (es) Composiciones farmaceuticas a base de taxoides.
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
ES2059408T3 (es) Un proceso para la preparacion de un compuesto.
ES2053864T3 (es) Derivados de acido 4-(quinolin-2-il-metoxi)fenil-acetico substituido.
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
ES2059491T3 (es) Derivados de indol con anillos condensados.
ES2075350T3 (es) Compuestos heterociclicos antiemeticos y supresores de la migraña, y composiciones farmaceuticas que los contienen.
PT83961B (pt) Processo para a preparacao de derivados da pirazolina e de composicoes insecticidas e acaricidas que os contem
DE3873550D1 (de) Photopolymerisierbare zusammensetzungen.
ES8600306A1 (es) Un procedimiento para la preparacion de derivados de penem-2-metil sustituidos.
DZ1468A1 (fr) Composés nouveaux.
AR002041A1 (es) Nuevos taxoides, procedimiento para prepararlos, los compuestos intermediarios de aplicacion con dicho procedimiento, procedimiento parapreparar dichos intermediarios y las composiciones farmaceuticas que contienen dichos taxoides.
ES2091310T3 (es) Nuevos derivados de la n-benzoil-prolina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX9204342A (es) Indoles.
ES8601908A1 (es) Procedimiento para la preparacion de nuevas 5,11-dihidro-6h-dibenzo (b,e)azepin-6-onas sustituidas
DE3871083D1 (de) Photopolymerisierbare zusammensetzungen.
ES2182090T3 (es) Nuevos derivados de pirrol.
PA8465101A1 (es) Compuestos de triazina
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2008109B3 (es) Procedimiento de preparacion de aminoalcoholes y de composiciones farmaceuticas que los contienen.
MX9203642A (es) Compuestos substituidos del acido 1,3,4,9-tetrahidropirano (3,4-b)-indol-1-acetico y composiciones farmaceuticas que los contienen.
DE3873562D1 (de) Beta-alkylmelatonine.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 296749

Country of ref document: ES